Surface Logix Raises $19.9 million from returning investors

Last week, Boston-based drug development company Surface Logix announced that it had raised $19.9 million in a Series D round from exiting investors Arch Venture Partners, Venrock, CW Group, Unilever Technology Ventures, and HBM BioVentures. The company, which is based off the work of Harvard’s Geor...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

More funding for Eat Just as it raises $90 million for its cell-based meat segment Good Meat

News Commentary | September 21, 2021

This investment closely follows the $170 million investment round in May 2021, bringing the company's total to $267 million. Eat Just has also added veterans from the USDA and DuPont to its board of directors. The company has made a string of announcements recently, including opening a manufacturing... Not part of subscription

Akili Interactive is going public, expected to net USD 412 million and open up investment opportunities

News Commentary | February 01, 2022

The company will be going public through a special purpose acquisition company known as Social Capital Suvretta Holdings Corp. Akili Interactive will use the expected cash proceeds to support the rollout of their U.S. FDA‑approved pediatric ADHD therapeutic, EndeavorRx. With EndeavorRX, Akili is ... Not part of subscription

Wildtype raises USD 100 million in Series B funding round to commercialize cell-based seafood

News Commentary | February 25, 2022

Led by L‑Catterton with participation from corporate investors including Cargill, this round brings Wildtype's total funding to USD 120 million. The cash infusion comes at the right time as the startup is looking to expand its production capacity of sushi‑grade, cell‑based salmon. Fish cells can be ... Not part of subscription